Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 6/20 | 0.73 |
| ▸ | NT5E | P21589 | 1/20 | 0.73 |
| ▸ | GSK3A | P49840 | 2/20 | 0.68 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.68 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.68 |
| ▸ | TGM2 | P21980 | 1/20 | 0.67 |
| ▸ | PNP | P00491 | 1/20 | 0.65 |
| ▸ | KRAS | P01116 | 5/20 | 0.61 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.59 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17355882 | 0.92 | HINT1 (0.73) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL3970953 | 0.92 | HINT1 (0.73) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL7098413 | 0.91 | HINT1 (0.67) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| 2'-Beta-Methyl-Guanosine SCHEMBL116165 | 0.91 | HINT1 (0.75) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL7111080 | 0.91 | HINT1 (0.72) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| 2'-Beta-Methyl-Guanosine SCHEMBL15338533 | 0.91 | HINT1 (0.75) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| 2'-Beta-Methyl-Guanosine SCHEMBL14178410 | 0.91 | HINT1 (0.75) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| 2'-Beta-Methyl-Guanosine SCHEMBL11965261 | 0.91 | HINT1 (0.75) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL2014087 | 0.91 | HINT1 (0.72) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| 2'-Beta-Methyl-Guanosine SCHEMBL383785 | 0.91 | HINT1 (0.75) | HINT1NT5EGSK3ARPS6KA3MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024192269-A2 | ENZYMATIC METHODS AND COMPOSITIONS FOR POLYMERIZATION OF PHOSPHORAMIDATE AND THIOPHOSPHORAMIDATE-LINKED DNA | THE GENERAL HOSPITAL CORPORATION (US) | 2024-09-19 | — | — | WO | claimed |
| CN-101340931-A | Modulation of tlr-mediated immune responses using adaptor oligonucleotides | COLEY PHARM GMBH (DE) | 2009-01-07 | — | — | CN | claimed |
| US-20080311040-A1 | METHODS AND COMPOSITIONS FOR IMPROVED THERAPEUTIC EFFECTS WITH siRNA | FLAGSHIP VENTURES (US) | 2008-12-18 | — | — | US | claimed |
| WO-2008109105-A2 | METHODS AND COMPOSITIONS FOR IMPROVED THERAPEUTIC EFFECTS WITH SIRNA | FLAGSHIP VENTURES (US) | 2008-09-12 | — | — | WO | claimed |
| CN-111527205-B | Novel method for synthesizing polynucleotides using diverse libraries of oligonucleotides | 里本生物实验室有限责任公司 | 2024-12-17 | — | — | CN | disclosed |
| WO-2024192269-A2 | ENZYMATIC METHODS AND COMPOSITIONS FOR POLYMERIZATION OF PHOSPHORAMIDATE AND THIOPHOSPHORAMIDATE-LINKED DNA | THE GENERAL HOSPITAL CORPORATION (US) | 2024-09-19 | — | — | WO | disclosed |
| EP-4399294-A1 | GUIDE RNAS WITH CHEMICAL MODIFICATION FOR PRIME EDITING | Agilent Technologies, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| US-12037335-B2 | Substituted purines as TLR7 agonists | Primmune Therapeutics, Inc. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240116974-A1 | TLR7 AGONISTS | Primmune Therapeutics, Inc. | 2024-04-11 | — | — | US | disclosed |
| EP-4298104-A1 | HYDROCINNAMOYL PROTECTED RIBOGUANOSINE PHOSPHORAMIDITES FOR DECREASING DEPYRIMIDINATION FROM ALKYL AMINE EXPOSURE DURING FINAL DEPROTECTION | Agilent Technologies, Inc. (US) | 2024-01-03 | — | — | EP | disclosed |
| CN-116981676-A | Cyano-protected riboguanosine phosphoramidites for reducing depyrimidition caused by alkylamine exposure during final deprotection | 安捷伦科技有限公司 | 2023-10-31 | — | — | CN | disclosed |
| WO-2022183081-A9 | HYDROCINNAMOYL PROTECTED RIBOGUANOSINE PHOSPHORAMIDITES FOR DECREASING DEPYRIMIDINATION FROM ALKYL AMINE EXPOSURE DURING FINAL DEPROTECTION | AGILENT TECHNOLOGIES, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| CN-101340931-A | Modulation of tlr-mediated immune responses using adaptor oligonucleotides | COLEY PHARM GMBH (DE) | 2009-01-07 | — | — | CN | disclosed |
| US-20080311040-A1 | METHODS AND COMPOSITIONS FOR IMPROVED THERAPEUTIC EFFECTS WITH siRNA | FLAGSHIP VENTURES (US) | 2008-12-18 | — | — | US | disclosed |
| EP-1986699-A2 | RNA INTERFERENCE AGENTS FOR THERAPEUTIC USE | University of Massachusetts (US) | 2008-11-05 | — | — | EP | disclosed |
| WO-2008109105-A2 | METHODS AND COMPOSITIONS FOR IMPROVED THERAPEUTIC EFFECTS WITH SIRNA | FLAGSHIP VENTURES (US) | 2008-09-12 | — | — | WO | disclosed |
| WO-2007092182-A2 | RNA INTERFERENCE AGENTS FOR THERAPEUTIC USE | UNIVERSITY OF MASSACHUSETTS (US) | 2007-08-16 | — | — | WO | disclosed |
| CN-1216991-C | Human guanosine monophophate reductase and its coding sequence and preparation method | UNIV FUDAN (CN) | 2005-08-31 | — | — | CN | disclosed |
| EP-0699763-B1 | Nucleic acid sequence encoding trypsin-like enzyme and process for producing the enzyme | TEIJIN LTD (JP) | 1998-09-30 | — | — | EP | disclosed |
| US-4500524-A | Tranquilizing and reducing or preventing seizures | TRUSTEES OF BOSTON UNIVERSITY (US) | 1985-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080311040-A1 | METHODS AND COMPOSITIONS FOR IMPROVED THERAPEUTIC EFFECTS WITH siRNA | NSUN3, AGO2, NSUN2 | HINT1 3970/4885NT5E 2089/4885GSK3A 3354/4885 |
| US-20240116974-A1 | TLR7 AGONISTS | TLR7, TLR1, TLR9 | HINT1 3939/4885NT5E 1404/4885GSK3A 3180/4885 |
| US-12037335-B2 | Substituted purines as TLR7 agonists | TLR7, TLR9, TLR1 | HINT1 811/4885NT5E 133/4885GSK3A 3393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.